A small molecule-kinase interaction map for clinical kinase inhibitors

被引：1588

作者：

Fabian, MA ^{[1
]}

Biggs, WH ^{[1
]}

Treiber, DK ^{[1
]}

Atteridge, CE ^{[1
]}

Azimioara, MD ^{[1
]}

Benedetti, MG ^{[1
]}

Carter, TA ^{[1
]}

Ciceri, P ^{[1
]}

Edeen, PT ^{[1
]}

Floyd, M ^{[1
]}

Ford, JM ^{[1
]}

Galvin, M ^{[1
]}

Gerlach, JL ^{[1
]}

Grotzfeld, RM ^{[1
]}

Herrgard, S ^{[1
]}

Insko, DE ^{[1
]}

Insko, MA ^{[1
]}

Lai, AG ^{[1
]}

Lélias, JM ^{[1
]}

Mehta, SA ^{[1
]}

Milanov, ZV ^{[1
]}

Velasco, AM ^{[1
]}

Wodicka, LM ^{[1
]}

Patel, HK ^{[1
]}

Zarrinkar, PP ^{[1
]}

Lockhart, DJ ^{[1
]}

机构：

[1] Ambit Biosci, San Diego, CA 92121 USA

来源：

NATURE BIOTECHNOLOGY | 2005年 / 23卷 / 03期

关键词：

D O I：

10.1038/nbt1068

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Kinase inhibitors show great promise as a new class of therapeutics. Here we describe an efficient way to determine kinase inhibitor specificity by measuring binding of small molecules to the ATP site of kinases. We have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clinical development, against a panel of 119 protein kinases. We find that specificity varies widely and is not strongly correlated with chemical structure or the identity of the intended target. Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LICK. We also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib. Our results represent a systematic small molecule-protein interaction map for clinical compounds across a large number of related proteins.

引用

页码：329 / 336

页数：8

共 47 条

[1] Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer
Allen, LF
Lenehan, PF
Eiseman, IA
Elliott, WL
Fry, DW
[J]. SEMINARS IN ONCOLOGY, 2002, 29 (03) : 11 - 21
[2] Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL
Azam, M
Latek, RR
Daley, GQ
[J]. CELL, 2003, 112 (06) : 831 - 843
[3] The specificities of protein kinase inhibitors: an update
Bain, J
McLauchlan, H
Elliott, M
Cohen, P
[J]. BIOCHEMICAL JOURNAL, 2003, 371 : 199 - 204
[4] SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
Bennett, BL
Sasaki, DT
Murray, BW
O'Leary, EC
Sakata, ST
Xu, WM
Leisten, JC
Motiwala, A
Pierce, S
Satoh, Y
Bhagwat, SS
Manning, AM
Anderson, DW
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (24) : 13681 - 13686
[5] High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
Branford, S
Rudzki, Z
Walsh, S
Grigg, A
Arthur, C
Taylor, K
Herrmann, R
Lynch, KP
Hughes, TP
[J]. BLOOD, 2002, 99 (09) : 3472 - 3475
[6] Bcr-Abl inhibition as a modality of CML therapeutics
Buchdunger, E
Matter, A
Druker, BJ
[J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2001, 1551 (01): : M11 - M18
[7] Protein kinases - the major drug targets of the twenty-first century?
Cohen, P
[J]. NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) : 309 - 315
[8] Issues and progress with protein kinase inhibitors for cancer treatment
Dancey, J
Sausville, EA
[J]. NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (04) : 296 - 313
[9] Specificity and mechanism of action of some commonly used protein kinase inhibitors
Davies, SP
Reddy, H
Caivano, M
Cohen, P
[J]. BIOCHEMICAL JOURNAL, 2000, 351 (351) : 95 - 105
[10] Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo
Dietz, AB
Souan, L
Knutson, GJ
Bulur, PA
Litzow, MR
Vuk-Pavlovi, S
[J]. BLOOD, 2004, 104 (04) : 1094 - 1099

← 1 2 3 4 5 →